ClinicalTrials.gg
TerminatedNCT02430532INSPIREUpdated Apr 26, 2017Results posted

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

A Phase 3 interventional study of dimethyl fumarate and Placebo in Multiple Sclerosis, Secondary Progressive, sponsored by Biogen. Terminated at 18 sites in 6 countries. Open to participants aged 18 Years to 58 Years. Per ClinicalTrials.gov, last updated 2017-04-26.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States — 25 open to participants now, 38 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · United States.

Enrollment
45th of 85
58 · median 59
Started
2015
with 4 others
Phase 3
20 of 105
4 open now
Registered
31st of 105
by date
Lead sponsor
3 of 105
Biogen

Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, this one is the 45th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 3, and was the 31st registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

25 of the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 58 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.

03

Conditions studied

  • Multiple Sclerosis, Secondary Progressive

Keywords

  • INSPIRE
  • SPMS
  • Tecfidera
  • BG00012
04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Onset of SPMS at least 1 to 2 years prior to randomization. SPMS is defined as relapsing-remitting disease followed by progression of disability independent of or not explained by relapses.
  • Have documented confirmed evidence of disease progression independent of clinical relapses over the 1 year prior to randomization.
  • Have an Expanded Disability Status Scale score of 3.0 to 6.5, inclusive.
  • Have a Multiple Sclerosis (MS) Severity Score of 4 or higher.

Key Exclusion Criteria:

  • Have a diagnosis of relapsing remitting multiple sclerosis or primary progressive MS as defined by the revised McDonald criteria.
  • Had a recent clinical relapse (within 3 months) prior to randomization.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; serious or acute liver, kidney, or bone marrow dysfunction; uncontrolled diabetes; serious or acute psychiatric illness that would limit compliance with study requirements.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Dimethyl fumarate

    BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.

    Drug: dimethyl fumarate · Other: Placebo

  • Experimental
    Placebo

    BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.

    Drug: dimethyl fumarate · Other: Placebo

Interventions

  • capsule

    Also known as: DMF, BG00012, Tecfidera

  • OtherPlacebo

    matched placebo capsule

06

What researchers measure

Primary outcomes

  1. Time to Disability Progression Independent of Relapse

    Time to onset of confirmed progression of disability is defined as 1 or more of the following criteria, confirmed at ≥ 6 months after start of treatment and at Week 108 using 1 or more of the following assessments: Expanded Disability Status Scale (EDSS) score increased from Baseline of ≥ 1 point if baseline EDSS ≤ 5.5, or ≥ 0.5 point if Baseline EDSS ≥ 6.0; Timed 25-Foot Walk (T25FW) ≥ 20% increase from Baseline in the time taken for the 25-foot walk; worsening on the 9-Hole Peg Test (9HPT; ≥ 20% increase from Baseline in the time taken for the 9HPT, confirmed in the same hand). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.

    Time frame: Up to 108 weeks

Secondary outcomes

  1. Change From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)

    MSWS-12 is a participant self-assessment of walking limitations due to multiple sclerosis (MS) during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater negative impact on walking.

    Time frame: Baseline, 2 years

  2. Change From Baseline to Week 108 in ABILHAND Questionnaire Score

    The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. Participants fill in the 56-item questionnaire by estimating their own difficulty or ease in performing each of the 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability.

    Time frame: Baseline, Week 108

  3. Percentage Change From Baseline to Week 108 in Whole Brain Volume

    Whole brain volume is measured by magnetic resonance imaging (MRI).

    Time frame: Baseline, Week 108

  4. Change From Baseline to Week 108 in Cognitive Function as Measured by the Symbol Digit Modalities Test (SDMT)

    The SDMT measures the time to pair abstract geometric symbols with specific numbers. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates a better outcome.

    Time frame: Baseline, Week 108

07

Results

Posted Mar 27, 2017
Limitations and caveats
The study was terminated early by the sponsor for business reasons. Efficacy, patient-reported outcomes, and pharmacodynamic data were not analyzed.

Participant flow

Participant flow — Overall Study
MilestonePlaceboTecfidera 240 mg BID
Started3028
Completed00
Not completed3028
Withdrew: Sponsor decision to stop study early3025
Withdrew: Consent withdrawn02
Withdrew: Adverse event01

Outcome measures

PrimaryTime to Disability Progression Independent of Relapse

Time to onset of confirmed progression of disability is defined as 1 or more of the following criteria, confirmed at ≥ 6 months after start of treatment and at Week 108 using 1 or more of the following assessments: Expanded Disability Status Scale (EDSS) score increased from Baseline of ≥ 1 point if baseline EDSS ≤ 5.5, or ≥ 0.5 point if Baseline EDSS ≥ 6.0; Timed 25-Foot Walk (T25FW) ≥ 20% increase from Baseline in the time taken for the 25-foot walk; worsening on the 9-Hole Peg Test (9HPT; ≥ 20% increase from Baseline in the time taken for the 9HPT, confirmed in the same hand). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.

Time frame:
Up to 108 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)

MSWS-12 is a participant self-assessment of walking limitations due to multiple sclerosis (MS) during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater negative impact on walking.

Time frame:
Baseline, 2 years

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 108 in ABILHAND Questionnaire Score

The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. Participants fill in the 56-item questionnaire by estimating their own difficulty or ease in performing each of the 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability.

Time frame:
Baseline, Week 108

No measurements were reported for this outcome.

SecondaryPercentage Change From Baseline to Week 108 in Whole Brain Volume

Whole brain volume is measured by magnetic resonance imaging (MRI).

Time frame:
Baseline, Week 108

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 108 in Cognitive Function as Measured by the Symbol Digit Modalities Test (SDMT)

The SDMT measures the time to pair abstract geometric symbols with specific numbers. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates a better outcome.

Time frame:
Baseline, Week 108

No measurements were reported for this outcome.

Adverse events

Collected over Up to approximately 24 weeks (overall mean time on study of 14.34, with an overall mean time on study treatment of 9.58 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/30 (0%)9/30 (30%)
Tecfidera 240 mg BID—5/28 (17.9%)9/28 (32.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboTecfidera 240 mg BID
EnteritisGastrointestinal disorders0/301/28
FallInjury, poisoning and procedural complications0/301/28
Femur fractureInjury, poisoning and procedural complications0/301/28
Multiple sclerosis relapseNervous system disorders0/301/28
Trigeminal neuralgiaNervous system disorders0/301/28
Calculus uretericRenal and urinary disorders0/301/28
NephrolithiasisRenal and urinary disorders0/301/28
Renal colicRenal and urinary disorders0/301/28
DyspnoeaRespiratory, thoracic and mediastinal disorders0/301/28
Most frequent other events
Most frequent other events
EventPlaceboTecfidera 240 mg BID
FlushingVascular disorders5/305/28
Urinary tract infectionInfections and infestations3/302/28
DiarrhoeaGastrointestinal disorders0/302/28
NauseaGastrointestinal disorders0/302/28
VomitingGastrointestinal disorders0/302/28
Multiple sclerosis relapseNervous system disorders0/302/28
Upper respiratory tract infectionInfections and infestations2/300/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTecfidera 240 mg BIDTotal
Mean50.7 ± 6.6749.6 ± 8.0550.2 ± 7.33
Age, Customized
Age, Customized(participants)PlaceboTecfidera 240 mg BIDTotal
< 20 years000
20 to 29 years000
30 to 39 years145
40 to 49 years10818
>= 50 years191635
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTecfidera 240 mg BIDTotal
Female191736
Male111122
08

Study locations

18 sites
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Tampa, Florida 33634, United States
  • Research Site
    Vero Beach, Florida 32960, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Willow Grove, Pennsylvania 19001, United States
  • Research Site
    Round Rock, Texas 78681, United States
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Brno, 656 91, Czech Republic
  • Research Site
    Hradec Kralove, 500 05, Czech Republic
  • Research Site
    Sittard-Geleen, 6162 BG, Netherlands
  • Research Site
    Gdansk, 80-803, Poland
  • Research Site
    Katowice, Poland
  • Research Site
    Krakow, 31-505, Poland
  • Research Site
    Lodz, 93-121, Poland
  • Research Site
    Plewiska, 62-064, Poland
  • Research Site
    Poznan, 61-853, Poland
  • Research Site
    Banska Bystrica, 97404, Slovakia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2015
First posted
Apr 30, 2015
Start
May 2015
Primary completionActual
Jan 2016
CompletionActual
Jan 2016
Results first posted
Mar 27, 2017
Last update
Apr 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02430532
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 30, 2015
Start date
May 2015
Primary completion
Jan 2016
Completion
Jan 2016
Results posted
Mar 27, 2017
Last update
Apr 26, 2017

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion